INTRODUCTION
Angiogenesis, the outgrowth of new capillaries from pre-existing vessels, is not only essential for a number of physiological processes but also occurs in many pathological conditions including tumor growth. This phenomenon is tightly controlled by numerous angiogenic factors whose effects are counterbalanced by inhibitory molecules such as Endostatin and Angiostatin which are proteolytic polypeptides derived from collagen XVIII and plasminogen, respectively (1, 2).
Among the angiogenic growth factors, FGF-2 is one of the most efficient (3) .
It can exert its activity both as an endogenous (intracrine) and an exogenous (auto-/paracrine) factor through different pathways. Exogenous FGF2 act via cell surface receptors linked to conventional signal transduction pathways, but also through direct association with the nuclei of target cells after internalisation and nuclear translocation during the G1 phase of the cell cycle (4) . We have recently shown that this nuclear translocation is necessary for the mitogenic activity of FGF-2 and is mediated by Translokin, isolated by the two-hybrid system with FGF-2 18 kDa as bait (5) .
In the same screening, we isolated two independent clones encoding fragments of Fibronectin that also showed a strong interaction with FGF-2. It has been previously reported that the amino-and carboxy-terminal heparin-binding domain of human plasma Fibronectin appear to be rather specific potent inhibitors of bovine aortic endothelial cell growth in culture by an unknown mechanism, whereas the plasma Fibronectin itself is much less inhibitory (6) . We thus evaluated whether the shortest of the two FGF-2 interacting fragments could counteract the angiogenic properties of FGF-2. Given its anti-angiogenic activity we named the fragment Fibstatin.
MATERIALS AND METHODS

Yeast two-hybrid system
The two-hybrid expression-cloning system was carried out as described by Van den Berghe et al. (8) . Briefly, the 18 kDa FGF-2 was used as bait, and the corresponding cDNA was inserted in the pAS2 vector. A human placenta library (Clontech, Palo Alto, CA) cloned into the pACT2 vector was screened in Saccharomyces cerevisiae strain Y190. ß-galactosidase activity of colonies growing on selection medium (DOBArg/-Trp/-Leu) was assessed by blue/white coloring (X-gal assay) and in yeast extracts using Galacto-Light (Tropix Inc. Bedford, MA) as described by the manufacturer. The activity was normalized for protein contents.
Plasmids encoding Fibstatin or Endostatin
The coding sequence of Fibstatin was amplified by PCR from the pACT2 plasmid containing the Fibstatin cDNA isolated by the two hybrid screening. The coding sequence of Endostatin was amplified by RT-PCR from RNA extracted from NIH-3T3 cells. The two cDNAs were then ligated into pET-15b (Novagen, Madison, WI) in frame with the histidine tag for recombinant protein production in E.coli or cloned in the eukaryotic expression vectors, pUHD10-3 (9) and pSCT (10) in frame with the signal peptide of VEGF-A (11) and the HA epitope, for use in conditioned media preparation and electrotransfer, respectively. For the structure-functional analysis of the FGF2-Fibstatin complex, given regions of Fibstatin were amplified by PCR, respecting the limits of each type III module (Fig. 1) . The amplified products were cloned in frame with the transactivating domain of Gal4 in pACT2 vector. All the sequences were confirmed by automatic sequencing using the ABI Prism Dye provided upon request.
Recombinant protein expression
Using E.coli BL21 (DE3). The production and purification of recombinant proteins were performed with Ni 2+ -NTA beads (Qiagen, Courtaboeuf, France) as described by
Holzinger et al. (12).
Using Baculovirus. The coding sequences for Fibstatin and Endostatin were subcloned into the transfer vector p119 designed for recombination in the P10 locus as described by Marchal et al. (13) . Briefly, by using DOTAP (Roche), Sf9 cells were cotransfected with p119-Fib or p119-Endo and purified viral DNA of baculovirus AcSLP10 expressing the polyhedrin gene under the control of the P10 promoter (14) .
The screening and purification of the recombinant virus were carried out as reported by Summers and Smith (15). Fibstatin and Endostatin were purified from the serumfree supernatant of Sf9 cells. The supernatant (1 liter) was slowly mixed with ammonium sulfate to obtain a final concentration of 50%. The ammonium sulfate/supernatant solution was stirred 2 hours at 4°C and centrifuged at 5000 rpm for 30 min. The precipitated proteins were resuspended in 0.1 starting volumes of PBS. The solution was dialyzed against PBS and the proteins were purified by using Ni 2+ -NTA beads according to the manufacturer (Qiagen).
Cell culture
NIH-3T3, HeLa HT (16) 
Cell migration assay
ABAE cells were grown to confluence in complete medium. The cells were then incubated in serum-free DMEM for 48h prior to the experiment. A scratch injury was applied on the cell monolayer using a plastic pipette tip to generate a wound. The debris were removed by washing the cells with PBS, and the cells were incubated for 14 h in serum-free DMEM supplemented with FGF-2 (3 ng/ml) in the presence or not (control) of Fibstatin (1µg/ml). Migrating cells were then counted under microscope.
In vitro angiogenesis assay
Twenty-four-well plates were coated with 300 µl Growth Factor Reduced Matrigel™ (B&D, Bedford, MA) per well, which was allowed to polymerize for 1h at 37°C.
ABAE cells (2x10 5 cells/ml) suspended in 500 µl of culture medium were then added to each well. FGF-2 (0.5 ng/ml) with or without (control) Fibstatin (1µg/ml) was added to the wells and the plates were incubated overnight at 37°C. After removal of the medium, the culture was fixed and the length of the tube network was quantified with the Q Win Leica system (Leica Microsystems, Rueil-Malmaison, France).
Animals studies
Six-to 10-week-old C57Bl/6 mice were housed in stainless-steel cages in groups of 5, kept in a temperature-controlled facility on a 12-h light-dark cycle, and fed normal laboratory mouse chow diet. All procedures were performed in accordance with the recommendations of the European Accreditation of Laboratory Animal Care. rpm, 10 minutes) and 20 µl of supernatant was used to measure the β-Galactosidase activity using the commercial kit Galacto Light (Tropix, Bedford, MA).
CD31 Immunostaining
Intratumoral microvessel density was analyzed on frozen sections (5 µm) of B16 melanoma using a rat anti-mouse CD31 monoclonal antibody (Pharmingen, San Diego, CA). After fixation in 4% paraformaldehyde for 1h at 4°C, the sections were washed 3 times with PBS and were permeabilized using PBS-0.25% Triton X100-3%
BSA for 1h. After blocking with 5% rabbit serum/PBS-Tween 0.1% for 1h at room temperature, the sections were incubated overnight with the anti-mouse CD31 
RESULTS
Isolation of a novel FGF-2 interacting protein
In a two-hybrid screening, we isolated two independent clones that interacted strongly with FGF-2 (Fig. 1A ). These two clones named A and B, contain the heparin binding domain 2 (hep2) of Fibronectin and mainly differ in the length of their NH2 extremities (Fig. 1B) . After a more substantial characterization of the properties of the shortest clone B (see below), which overlaps with the three type III modules (FNIII 12-14) of Fibronectin, we named the corresponding peptide Fibstatin.
To test the specificity of the observed interaction between Fibstatin and FGF-2, we coexpressed Fibstatin in yeast with a panel of representative FGF-family members (FGF-1, FGF-3, FGF-6, FGF-12). Among the FGFs tested, only FGF-2 was able to interact with Fibstatin ( Fig. 2A) . To ascertain that the Fibstatin/FGF-2 interaction was direct and independent of a third partner, we expressed the two proteins in E.coli, purified them and tested their interaction in an in vitro ELISA assay as described by Bossard et al. (5) . Fibstatin and FGF-2 interact strongly in a direct and dosedependent manner (Fig. 2B) . We next determined which of the three type III modules in Fibstatin that contains the FGF-2 interacting site. Different portions of Fibstatin were subcloned in pACT2 and their capacity to interact with FGF-2 was tested in the two-hybrid system. We found that both FNIII 13 and 14 are necessary to maintain a similar level of binding as full length Fibstatin (Fig. 2C) . When tested separately, the two modules were not able to interact with FGF-2, except for a residual interaction (10%) for FNIII 14. These results suggest that two structural motifs in Fibstatin, the type III modules 13 and 14, cooperate in the binding to FGF-2.
Fibstatin inhibits endothelial cells proliferation
Since FGF-2 is a strong inducer of endothelial cell proliferation, Fibstatin was tested for its activity on FGF-2-induced proliferation of ABAE cells and compared with the inhibitory activity of Endostatin. For this purpose, we prepared conditioned media from transiently transfected HeLa HT. The presence of Fibstatin or Endostatin, which have an apparent molecular weight of 29 kDa and 20 kDa, respectively, was confirmed by SDS-PAGE (data not shown). The conditioned media were then applied at different dilutions to FGF-2-stimulated ABAE cells, in a 72 h proliferation assay.
Fibstatin and Endostatin expressed in the conditioned media inhibited in a dosedependent manner the ABAE proliferation induced by FGF-2 (Fig. 3A) . A similar inhibitory effect on ABAE cells was observed when recombinant Fibstatin produced in E.coli was used in the above assay (Fig. 3B) . Interestingly, the inhibitory effect of Fibstatin was greater compared to that of Endostatin, at every dose tested. On the contrary, no significant inhibition of proliferation was observed when cells of nonendothelial origin, such as fibroblasts NIH-3T3 or B16F10, were tested (Fig. 3C ).
Fibstatin inhibits endothelial cells migration and tubulogenesis
To test the ability of recombinant Fibstatin to inhibit endothelial cell migration induced by FGF-2, we used an in vitro wounding assay. The addition of 1 µg/ml
Fibstatin greatly reduced the number of migrating ABAE cells upon FGF-2 stimulation (Fig. 4A) . To determine the in vitro antiangiogenic effects of Fibstatin, we tested its ability to interfere with endothelial cell tube formation in Matrigel, a solid gel of basement membrane proteins derived from mouse sarcoma. When FGF-2 stimulated ABAE cells were cultured on Matrigel, they rapidly aligned and formed hollow tube-like structures. In the presence of Fibstatin produced in E.coli, the tube formation induced by FGF-2 was inhibited and the cells appeared clustered, as in the absence of FGF-2 (Fig. 4B) .
In vivo antiangiogenic activities of Fibstatin
We then tested the ability of recombinant Fibstatin to inhibit in vivo angiogenesis. Interestingly, Fibstatin was more potent than Endostatin in inhibiting the angiogenic activity of FGF-2 (Fig. 5A ). One could argue that this result is due to an effect of Fibstatin on matrix degrading protease, provoking matrigel degradation and the apparent decrease in cell number per unit matrigel weight. We then considered the cell numbers without normalizing them. As shown in Fig. 4A , even if the inhibition is lower in this condition (40%), it is still significant, consistent with an antiangiogenic activity of Fibstatin.
Electrotransfer of Fibstatin-encoding cDNA into muscles inhibits B16F10 tumor growth
We then evaluated the in vivo effect of Fibstatin on tumor growth after DNA electrotransfer. Fibstatin-or Endostatin-encoding plasmid DNA were mixed with a reporter plasmid encoding LacZ, injected and electroporated into quadriceps of C57Bl/6 mice, previously inoculated with B16F10 cells. The electroporation was repeated 5 days later. In the group of mice treated with the Fibstatin-coding gene, there was a 50% inhibition of tumor growth compared to control mice injected with empty vector. This inhibition was observed at day 10 ( Fig. 5B ) and also at day 14 (data not shown). Tumor mass in the Endostatin-treated group was reduced, but the difference did not reach statistical significance (Fig. 5B) . To assess the efficiency of the gene transfer, the β-galactosidase activity was measured in muscle lysate. The results, shown in Fig. 5C , reveal a significant β-galactosidase activity in all electroporated mice.
The circulating Endostatin level was determined by the use of a commercially available ELISA kit. Endostatin level in the blood of mice electrotransferred with a plasmid encoding Endostatin was markedly higher than in the blood of control mice (Fig. 5D) . In order to detect the level of circulating Fibstatin, we developed a rabbit polyclonal antibody which specifically recognizes the protein but was insufficient to detect low concentrations of the protein (data not shown). Even though we were unable to quantify the amount of circulating Fibstatin, the efficiency of the electrotransfer was ascertained by the quantification of the ß-Galactosidase activity in the transfected muscles (Fig. 5C) . Moreover, the transgene expression from both plasmids is similar when transfected in mammalian cells (data not shown).
Fibstatin inhibits tumor angiogenesis
To elucidate whether the effect of Fibstatin gene delivery on melanoma growth was due to an inhibition of angiogenesis, tumor capillaries were examined by anti-CD31
immunostaining. As shown in This property is collectively interpreted as involved in the inhibition of FGF/VEGF activity by competing for their interaction with HSPG. Indeed, these two angiogenic factors present a strong heparin binding activity.
It thus appears that at least two modes of action could be invoked for Fibstatin: the binding to HSPG and the direct protein-protein interaction with FGF-2. In addition,
we could also speculate that Fibstatin acts by binding to integrins. Indeed Fibstatin corresponds to the 12-14 type III domain, which binds to α IIb β 3 (26) and α 4 β 1 (27) .
Moreover, it has been recently shown that two other antiangiogenic factors, Tumstatin and Endostatin, exhibit their activities through α v β 3 and α 5 β 1 integrins (28) .
The characterization of novel antiangiogenic proteins and the elucidation of their mode of action is of great importance. Indeed, it would allow to consider associative strategies by using electrotransfer of polycistronic vectors expressing in the same time several antiangiogenic peptides with different properties in order to obtain an optimal angiogenesis inhibition. The type III(12) domain is in italics, the type III (13) domain is in bold and the type III (14) domain is underlined. 
